High Mobility Group Box-1: A Missing Link between Diabetes and Its Complications

Mediators of Inflammation

Volumn 2016, Issue , 2016, Pages

  Wu, Han ^a   Chen, Zheng ^a   Xie, Jun ^a   Kang, Li Na ^a   Wang, Lian ^a   Xu, Biao ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; HMGB1 PROTEIN, HUMAN; INSULIN;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; HUMAN; NONHUMAN; REVIEW; ANIMAL; APOPTOSIS; CYTOLOGY; DEFICIENCY; DIABETIC COMPLICATION; DISEASE COURSE; INFLAMMATION; INSULIN RESISTANCE; METABOLISM; OXIDATIVE STRESS; PANCREAS ISLET; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HMGB1 PROTEIN; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84994406656     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2016/3896147     Document Type: Review

References (92)

1. G. H. Goodwin, C. Sanders, and E. W. Johns, "A new group of chromatin-associated proteins with a high content of acidic and basic amino acids, " European Journal of Biochemistry, vol. 38, no. 1, pp. 14-19, 1973.
2. G. H. Goodwin and E. W. Johns, "The isolation and purification of the high mobility group (HMG) nonhistone chromosomal proteins, "Methods in Cell Biology, vol. 16, pp. 257-267, 1977.
3. D. Musumeci, G. N. Roviello, and D. Montesarchio, "An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies, " Pharmacology and Therapeutics, vol. 141, no. 3, pp. 347-357, 2014.
4. R. Kang, R. Chen, Q. Zhang et al., "HMGB1 in health and disease, " Molecular Aspects of Medicine, vol. 40, pp. 1-116, 2014.
5. J. Cai, J. Wen, E. Bauer, H. Zhong, H. Yuan, and A. F. Chen, "The role of HMGB1 in cardiovascular biology: danger signals, " Antioxidants and Redox Signaling, vol. 23, no. 17, pp. 1351-1369, 2015.
6. H. Yang, H. Wang, Y. A. Levine et al., "Identification of CD163 as an antiinflammatory receptor forHMGB1-haptoglobin complexes, " JCI Insight, vol. 1, no. 7, 2016.
7. J. R. van Beijnum, W. A. Buurman, and A. W. Griffioen, "Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1), " Angiogenesis, vol. 11, no. 1, pp. 91-99, 2008.
8. F.-C. Wang, J.-X. Pei, J. Zhu et al., "Overexpression of HMGB1 A-box reduced lipopolysaccharide-induced intestinal inflammation via HMGB1/TLR4 signaling in vitro, " World Journal of Gastroenterology, vol. 21, no. 25, pp. 7764-7776, 2015.
9. D. Zabini, S. Crnkovic, H. Xu et al., "High-mobility group box-1 induces vascular remodelling processes via c-Jun activation, " Journal of Cellular and Molecular Medicine, vol. 19, no. 5, pp. 1151-1161, 2015.
10. S. Vogel, R. Bodenstein, Q. Chen et al., "Platelet-derived HMGB1 is a critical mediator of thrombosis, " Journal of Clinical Investigation, vol. 125, no. 12, pp. 4638-4654, 2015.
11. W. S. Yang, J.-S. Kim, N. J. Han, M. J. Lee, and S.-K. Park, "Tolllike receptor 4/spleen tyrosine kinase complex in high glucose signal transduction of proximal tubular epithelial cells, " Cellular Physiology and Biochemistry, vol. 35, no. 6, pp. 2309-2319, 2015.
12. Z. Su, H. Lu, H. Jiang et al., "IFN-producing Th17 cells bias by HMGB1-T-bet/RUNX3 axis might contribute to progression of coronary artery atherosclerosis, " Atherosclerosis, vol. 243, no. 2, pp. 421-428, 2015.
13. M. K. Gunasekaran, W. Viranaicken, A.-C. Girard et al., "Inflammation triggers high mobility group box 1 (HMGB1) secretion in adipose tissue, a potential link to obesity, " Cytokine, vol. 64, no. 1, pp. 103-111, 2013.
14. G. Ozer, Z. Teker, S. Cetiner et al., "Serum IL-1, IL-2, TNFalpha and INFgamma levels of patients with type 1 diabetes mellitus and their siblings, " Journal of Pediatric Endocrinology and Metabolism, vol. 16, no. 2, pp. 203-210, 2003.
15. S. J. Richardson, A. Willcox, A. J. Bone, A. K. Foulis, and N. G. Morgan, "Islet-associated macrophages in type 2 diabetes, " Diabetologia, vol. 52, no. 8, pp. 1686-1688, 2009.
16. C. Herder, E. Dalmas, M. Böni-Schnetzler, and M. Y. Donath, "The IL-1 pathway in type 2 diabetes and cardiovascular complications, " Trends in Endocrinology and Metabolism, vol. 26, no. 10, pp. 551-563, 2015.
17. E. J. P. vanAsseldonk, P. C. M. vanPoppel, D. B. Ballak, R. Stienstra, M. G. Netea, andC. J. Tack, "One week treatmentwith the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients withtype 1 diabetes mellitus, " Clinical Immunology, vol. 160, no. 2, pp. 155-162, 2015.
18. H. E. Thomas, W. Irawaty, R. Darwiche et al., "IL-1 receptor deficiency slows progression to diabetes in the NOD mouse, " Diabetes, vol. 53, no. 1, pp. 113-121, 2004.
19. J. Sloan-Lancaster, E. Abu-Raddad, J. Polzer et al., "Doubleblind, randomized study evaluating the glycemic and antiinflammatory effects of subcutaneous LY2189102, a neutralizing IL-1 antibody, in patients with type 2 diabetes, " Diabetes Care, vol. 36, no. 8, pp. 2239-2246, 2013.
20. H. Khodabandehloo, S. Gorgani-Firuzjaee, G. Panahi, and R. Meshkani, "Molecular and cellular mechanisms linking inflammation to insulin resistance and-cell dysfunction, " Translational Research, vol. 167, no. 1, pp. 228-256, 2016.
21. X. X. Yan, L. Lu, W. H. Peng et al., "Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients, " Atherosclerosis, vol. 205, no. 2, pp. 544-548, 2009.
22. J. ?Skrha, M. Kalousová, J. ?Svarcová et al., "Relationship of soluble RAGE and RAGE ligands HMGB1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes mellitus, " Experimental and Clinical Endocrinology and Diabetes, vol. 120, no. 5, pp. 277-281, 2012.
23. M. R. Dasu, S. Devaraj, S. Park, and I. Jialal, "Increased Toll-Like Receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects, " Diabetes Care, vol. 33, no. 4, pp. 861-868, 2010.
24. H. Wang, H. Qu, and H. Deng, "Plasma HMGB-1 levels in subjectswith obesity and type 2 diabetes: A cross-sectional study in China, " PLoS ONE, vol. 10, no. 8, Article IDe0136564, 2015.
25. L. Montanini, F. Cirillo, A. Smerieri et al., "HMGB1 is increased by CFTR loss of function, is lowered by insulin, and increases in vivo at onset of CFRD, " The Journal of Clinical Endocrinology &Metabolism, vol. 101, no. 3, pp. 1274-1281, 2016.
26. P. Dandona, H. Ghanim, K. Green et al., "Insulin infusion suppresses while glucose infusion induces toll-like receptors and high-mobility group-B1 protein expression inmononuclear cells of type 1 diabetes patients, " American Journal of Physiology-Endocrinology and Metabolism, vol. 304, no. 8, pp. E810-E818, 2013.
27. H. Wu, R. Li, Z.-H. Wei et al., "Diabetes-induced oxidative stress in endothelial progenitor cells may be sustained by a positive feedback loop involving high mobility group box-1, " Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 1943918, 9 pages, 2016.
28. W.-K. Wang, Q.-H. Lu, J.-N. Zhang et al., "HMGB1 mediates hyperglycaemia-induced cardiomyocyte apoptosis via ERK/ Ets-1 signalling pathway, " Journal of Cellular and Molecular Medicine, vol. 18, no. 11, pp. 2311-2320, 2014.
29. X.-L. Chen, X.-D. Zhang, Y.-Y. Li, X.-M. Chen, D.-R. Tang, and R.-J. Ran, "Involvement of HMGB1 mediated signalling pathway in diabetic retinopathy: evidence from type 2 diabetic rats andARPE-19 cells under diabetic condition, " British Journal of Ophthalmology, vol. 97, no. 12, pp. 1598-1603, 2013.
30. Y. Wang, J. Shan, W. Yang, H. Zheng, and S. Xue, "Highmobility group box 1 (HMGB1) mediates high-glucose-induced calcification in vascular smooth muscle cells of saphenous veins, " Inflammation, vol. 36, no. 6, pp. 1592-1604, 2013.
31. D. Yao and M. Brownlee, "Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands, " Diabetes, vol. 59, no. 1, pp. 249-255, 2010.
32. A. Soro-Paavonen, A. M. D. Watson, J. Li et al., "Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes, " Diabetes, vol. 57, no. 9, pp. 2461-2469, 2008.
33. C. Koulis, J. B. De Haan, and T. J. Allen, "Novel pathways and therapies in experimental diabetic atherosclerosis, " Expert Review of Cardiovascular Therapy, vol. 10, no. 3, pp. 323-335, 2012.
34. L. Feng, M. Zhu, M. Zhang et al., "Amelioration of compound 4, 4-diphenylmethane-bis(methyl)carbamate on high mobility group box1-mediated inflammation and oxidant stress responses in human umbilical vein endothelial cells via RAGE/ERK1/ 2/NF-B pathway, " International Immunopharmacology, vol. 15, no. 2, pp. 206-216, 2013.
35. M. Cheng, H. Liu, D. Zhang et al., "HMGB1 enhances the AGEinduced expression of CTGF and TGF-via RAGE-dependent signaling in renal tubular epithelial cells, " American Journal of Nephrology, vol. 41, no. 3, pp. 257-266, 2015.
36. K. Fukami, S.-I. Yamagishi, and S. Okuda, "Role ofAGEs-RAGE system in cardiovascular disease, " Current Pharmaceutical Design, vol. 20, no. 14, pp. 2395-2402, 2014.
37. B.-W. Lee, H. Y. Chae, S. J. Kwon, S. Y. Park, J. Ihm, and S.-H. Ihm, "RAGE ligands induce apoptotic cell death of pancreatic beta-cells via oxidative stress, " International Journal ofMolecular Medicine, vol. 26, no. 6, pp. 813-818, 2010.
38. J. J. Kim and D. D. Sears, "TLR4 and insulin resistance, " Gastroenterology Research and Practice, vol. 2010, Article ID 212563, 11 pages, 2010.
39. N. Zhang, H. Liang, R. V. Farese, J. Li, N. Musi, and S. E. Hussey, "Pharmacological TLR4 inhibition protects against acute and chronic fat-induced insulin resistance in rats, " PLoS ONE, vol. 10, no. 7, Article ID e0132575, 2015.
40. R. Guzmán-Ruiz, F. Ortega, A. Rodrguez et al., "Alarmin highmobility group B1 (HMGB1) is regulated in human adipocytes in insulin resistance and influences insulin secretion in-cells, " International Journal of Obesity, vol. 38, no. 12, pp. 1545-1554, 2014.
41. D. Zhao, Y. Wang, K. Tang, andY. Xu, "Increased serumHMGB1 related with HbA1c in coronary artery disease with type 2 diabetes mellitus, " International Journal of Cardiology, vol. 168, no. 2, pp. 1559-1560, 2013.
42. A. Yamashita, K. Nishihira, Y. Matsuura et al., "Paucity of CD34-positive cells and increased expression of high-mobility group box 1 in coronary thrombus with type 2 diabetes mellitus, " Atherosclerosis, vol. 224, no. 2, pp. 511-514, 2012.
43. F. Delucchi, R. Berni, C. Frati et al., "Resveratrol treatment reduces cardiac progenitor cell dysfunction and prevents morpho-functional ventricular remodeling in type-1 diabetic rats, " PLoS ONE, vol. 7, no. 6, article e39836, 2012.
44. W.-K. Wang, B. Wang, Q.-H. Lu et al., "Inhibition of highmobility group box 1 improves myocardial fibrosis and dysfunction in diabetic cardiomyopathy, " International Journal of Cardiology, vol. 172, no. 1, pp. 202-212, 2014.
45. T. Zhang, X. Hu, Y. Cai, B. Yi, and Z. Wen, "Metformin protects against hyperglycemia-induced cardiomyocytes injury byinhibiting the expressions of receptor for advanced glycation end products and highmobility group box 1 protein, "Molecular Biology Reports, vol. 41, no. 3, pp. 1335-1340, 2014.
46. C. F. Tsao, W. T. Huang, T. T. Liu et al., "Expression of highmobility group box protein 1 in diabetic foot Atherogenesis, " Genetics and Molecular Research, vol. 14, no. 2, pp. 4521-4531, 2015.
47. H. C. Volz, C. Seidel, D. Laohachewin et al., "HMGB1: The missing link between diabetes mellitus and heart failure, " Basic Research in Cardiology, vol. 105, no. 6, pp. 805-820, 2010.
48. M. Lin, W. H. Yiu, H. J. Wu et al., "Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy, " Journal of the American Society of Nephrology, vol. 23, no. 1, pp. 86-102, 2012.
49. F. Li, N. Yang, L. Zhang et al., "Increased expression of tolllike receptor 2 in rat diabetic nephropathy, " American Journal of Nephrology, vol. 32, no. 2, pp. 179-186, 2010.
50. J. Ma, S. J. Chadban, C. Y. Zhaoet al., "TLR4activationpromotes podocyte injury and interstitial fibrosis in diabetic nephropathy, " PLoS ONE, vol. 9, no. 5, Article ID e97985, 2014.
51. Y. Chen, F. Qiao, Y. Zhao, Y. Wang, and G. Liu, "HMGB1 is activated in type 2 diabetes mellitus patients and in mesangial cells in response to high glucose, " International Journal of Clinical and Experimental Pathology, vol. 8, no. 6, pp. 6683-6691, 2015.
52. J. Yang, L. Chen, J. Ding et al., "MicroRNA-24 inhibits high glucose-induced vascular smooth muscle cell proliferation and migration by targeting HMGB1, " Gene, vol. 586, no. 2, pp. 268-273, 2016.
53. A. M. Abu El-Asrar, M. I. Nawaz, D. Kangave, M. Abouammoh, and G. Mohammad, "High-mobility group box-1 and endothelial cell angiogenic markers in the vitreous from patients with proliferative diabetic retinopathy, " Mediators of Inflammation, vol. 2012, Article ID697489, 7 pages, 2012.
54. A. M. A. El-Asrar, G. Mohammad, M. I. Nawaz, andM. M. Siddiquei, "High-mobility group box-1 modulates the expression of inflammatory and angiogenic signaling pathways in diabetic retina, " Current Eye Research, vol. 40, no. 11, pp. 1141-1152, 2015.
55. A. M. Abu El-Asrar, M. Imtiaz Nawaz, D. Kangave, M. M. Siddiquei, and K. Geboes, "Osteopontin and other regulators of angiogenesis and fibrogenesis in the vitreous from patients with proliferative vitreoretinal disorders, " Mediators of Inflammation, vol. 2012, Article ID 493043, 8 pages, 2012.
56. J.-J. Lee, C.-C. Hsiao, I.-H. Yang et al., "High-mobility group box 1 protein is implicated in advanced glycation end productsinduced vascular endothelial growth factor a production in the rat retinal ganglion cell line RGC-5, " Molecular Vision, vol. 18, pp. 838-850, 2012.
57. A. M. A. El-Asrar, M. I. Nawaz, D. Kangave et al., "High-mobility group box-1 and biomarkers of inflammation in the vitreous frompatients with proliferative diabetic retinopathy, "Molecular Vision, vol. 17, pp. 1829-1838, 2011.
58. G. Mohammad, M. M. Siddiquei, A. Othman, M. Al-Shabrawey, and A. M. Abu El-Asrar, "High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina, " Experimental Eye Research, vol. 107, pp. 101-109, 2013.
59. J. Kim, C. S. Kim, E. Sohn et al., "Cytoplasmic translocation of high-mobility group box-1 protein is induced by diabetes and high glucose in retinal pericytes, " Molecular Medicine Reports, vol. 14, no. 4, pp. 3655-3661, 2016.
60. H. Zhao, J. Zhang, and J. Yu, "HMGB-1 as a potential target for the treatment of diabetic retinopathy, "Medical ScienceMonitor, vol. 21, pp. 3062-3067, 2015.
61. G. Mohammad, K. Alam, M. I. Nawaz, M. M. Siddiquei, A. Mousa, andA. M. Abu El-Asrar, "Mutual enhancement between high-mobility group box-1 and NADPH oxidase-derived reactive oxygen species mediates diabetes-induced upregulation of retinal apoptotic markers, " Journal of Physiology and Biochemistry, vol. 71, no. 3, pp. 359-372, 2015.
62. Y. Yu, L. Yang, J. Lv et al., "The role of high mobility group box 1 (HMGB-1) in the diabetic retinopathy inflammation and apoptosis, " International Journal of Clinical and Experimental Pathology, vol. 8, no. 6, pp. 6807-6813, 2015.
63. A. M. Abu El-Asrar, M. I. Nawaz, M. M. Siddiquei, A. S. Al-Kharashi, D. Kangave, and G. Mohammad, "High-mobility group box-1 induces decreased brain-derived neurotrophic factor-mediated neuroprotection in the diabetic retina, " Mediators of Inflammation, vol. 2013, Article ID863036, 11 pages, 2013.
64. T. Hashimoto, J. Ishii, F. Kitagawa et al., "Circulating highmobility group box 1 and cardiovascular mortality in unstable angina and non-ST-segment elevation myocardial infarction, " Atherosclerosis, vol. 221, no. 2, pp. 490-495, 2012.
65. M. Andrassy, H. C. Volz, A. Schuessler et al., "HMGB1 is associated with atherosclerotic plaque composition and burden in patients with stable coronary artery disease, " PLoS ONE, vol. 7, no. 12, Article ID e52081, 2012.
66. S. Haghjooy-Javanmard, M. Sadeghi, S. Safavi, M. Gheraati, and N. Dana, "Prognostic value of the high-mobility group box-1 in young patients with chest pain, " ARYA Atherosclerosis, vol. 10, no. 3, pp. 154-158, 2014.
67. K. Peter and A. Bobik, "HMGB1 signals danger in acute coronary syndrome: emergence of a new risk marker for cardiovascular death?" Atherosclerosis, vol. 221, no. 2, pp. 317-318, 2012.
68. J. W. M. Nin, I. Ferreira, C. G. Schalkwijk et al., "Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-causemortality in type 1 diabetes: A 12 Year Follow-up Study, " Diabetologia, vol. 55, no. 9, pp. 2489-2493, 2012.
69. T. Ito, K. Kawahara, T. Nakamura et al., "High-mobility group box 1 protein promotes development of microvascular thrombosis in rats, " Journal ofThrombosis and Haemostasis, vol. 5, no. 1, pp. 109-116, 2007.
70. L. J. Wang, L. Lu, F. R. Zhang, Q. J. Chen, R. De Caterina, and W. F. Shen, "Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure, " European Journal of Heart Failure, vol. 13, no. 4, pp. 440-449, 2011.
71. W. Zhang, K. J. Lavine, S. Epelman et al., "Necrotic myocardial cells release damage-associatedmolecular patterns that provoke fibroblast activation in vitro and trigger myocardial inflammation and fibrosis in vivo, " Journal of the American Heart Association, vol. 4, no. 6, Article ID e001993, 2015.
72. Z. Su, J. Yin, T. Wang et al., "Up-regulated HMGB1 in EAM directly led to collagen deposition by a PKC/Erk1/2-dependent pathway: cardiac fibroblast/myofibroblast might be anothersource of HMGB1, " Journal of Cellular and Molecular Medicine, vol. 18, no. 9, pp. 1740-1751, 2014.
73. Y. Yu, M. Liu, L. Zhang et al., "Heat shock transcription factor 1 inhibits H2O2-induced cardiomyocyte death through suppression of high-mobility group box 1, " Molecular and Cellular Biochemistry, vol. 364, no. 1-2, pp. 263-269, 2012.
74. P. Palsamy and S. Subramanian, "Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling, " Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1812, no. 7, pp. 719-731, 2011.
75. J. Kim, E. Sohn, C.-S. Kim, K. Jo, and J. S. Kim, "The role of highmobility group box-1 protein in the development of diabetic nephropathy, " American Journal of Nephrology, vol. 33, no. 6, pp. 524-529, 2011.
76. S. A. Penfold, M. T. Coughlan, S. K. Patel et al., "Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy, " Kidney International, vol. 78, no. 3, pp. 287-295, 2010.
77. I. Jialal, A. M. Major, and S. Devaraj, "Global toll-like receptor 4 knockout results in decreased renal inflammation, fibrosis and podocytopathy, " Journal of Diabetes and its Complications, vol. 28, no. 6, pp. 755-761, 2014.
78. M. D. Oldfield, L. A. Bach, J. M. Forbes et al., "Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE), " Journal of Clinical Investigation, vol. 108, no. 12, pp. 1853-1863, 2001.
79. K. C. Sourris, A. L. Morley, A. Koitka et al., "Receptor for AGEs (RAGE) blockademay exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor, " Diabetologia, vol. 53, no. 11, pp. 2442-2451, 2010.
80. Y. Yu, D. Tang, and R. Kang, "Oxidative stress-mediated HMGB1 biology, " Frontiers in Physiology, vol. 6, article 93, 2015.
81. Y. M. Lee, J. Kim, K. Jo et al., "Ethyl pyruvate inhibits retinal pathogenic neovascularization by downregulating HMGB1 expression, " Journal of Diabetes Research, vol. 2013, Article ID 245271, 8 pages, 2013.
82. G. Mohammad, D. Jomar, M. M. Siddiquei, K. Alam, and A. M. Abu El-Asrar, "High-mobility group box-1 proteinmediates the regulation of signal transducer and activator of transcription-3 in the diabetic retina and in human retinal muller cells, " Ophthalmic Research, 2016.
83. L. Han, M. Zhang, M. Wang et al., "High mobility group box-1 promotes inflammation-induced lymphangiogenesis via tolllike receptor 4-dependent signalling pathway, " PLoS ONE, vol. 11, no. 4, Article ID e0154187, 2016.
84. F. F. Zhang, N. Morioka, S. Harano et al., "Perineural expression of high-mobility group box-1 contributes to long-lasting mechanical hypersensitivity via matrix metalloprotease-9 upregulation in mice with painful peripheral neuropathy, " Journal of Neurochemistry, vol. 136, no. 4, pp. 837-850, 2016.
85. F. L. Cardoso, J. Herz, A. Fernandes et al., "Systemic inflammation in early neonatal mice induces transient and lasting neurodegenerative effects, " Journal of Neuroinflammation, vol. 12, article 82, 2015.
86. A. M. Abu El-Asrar, M. M. Siddiquei, M. I. Nawaz, K. Geboes, and G. Mohammad, "The proinflammatory cytokine highmobility group box-1 mediates retinal neuropathy induced by diabetes, " Mediators of Inflammation, vol. 2014, Article ID 746415, 10 pages, 2014.
87. H. Diao, Z. Kang, F. Han, and W. Jiang, "Astilbin protects diabetic rat heart against ischemia-reperfusion injury via blockade of HMGB1-dependent NF-B signaling pathway, " Food and Chemical Toxicology, vol. 63, pp. 104-110, 2014.
88. S. S. Dhumale, B. N. Waghela, and C. Pathak, "Quercetin protects necrotic insult and promotes apoptosis by attenuating the expression of RAGE and its ligand HMGB1 in human breast adenocarcinoma cells, " IUBMB Life, vol. 67, no. 5, pp. 361-373, 2015.
89. V. Karuppagounder, S. Arumugam, R. A. Thandavarayan et al., "Modulation of HMGB1 translocation and RAGE/NFB cascade by quercetin treatment mitigates atopic dermatitis in NC/ Nga transgenic mice, " Experimental Dermatology, vol. 24, no. 6, pp. 418-423, 2015.
90. D. Tang, R. Kang, W. Xiao et al., "Quercetin prevents LPSinduced high-mobility group box 1 release and proinflammatory function, " American Journal of Respiratory Cell and Molecular Biology, vol. 41, no. 6, pp. 651-660, 2009.
91. L. Wang, X. Zhang, L. Liu, R. Yang, L. Cui, andM. Li, "Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4), NF-B expression, " Neuroscience Letters, vol. 471, no. 3, pp. 152-156, 2010.
92. M. Liu, Y. Yu, H. Jiang et al., "Simvastatin suppresses vascular inflammation and atherosclerosis inApoE-/-mice by downregulating the HMGB1-RAGE axis, " Acta Pharmacologica Sinica, vol. 34, no. 6, pp. 830-836, 2013.